Comparison of effect of nifedipine, labetalol and methyldopa in treatment of hypertension in pregnancy in a tertiary care government hospital


  • Vibhuti Thakur Department of Obstetrics & Gynaecology, M.G.M Medical College, Indore, India
  • Ashok Thakur Department of Medicine, M.G.M Medical College, Indore, India
  • Satish Saroshe Department of Community Medicine, M.G.M Medical College, Indore, India



Preeclampsia, Antihypertensive drugs


Background: To know the incidence & demographic aspects of hypertensive disorders in pregnancy and to compare effect of nifedipine, labetalol, methyldopa on various aspects of PIH such as control of BP, proteinuria, gestational age on admission & of delivery and maternal & perinatal outcome.

Methods: Study was conducted in M.Y. Hospital, Indore for one year of period. Three groups each of 50 pts were given nifedipine, labetalol, and methyldopa. Groups were compared on basis of age, residence, parity, control of BP, proteinuria, gestational age of delivery maternal complication &perinatal outcome.

Results: maximum patients were from younger age group and mostly are primigravida. Fall in systolic & diastolic BP is significant in all 3 groups. Incidence of decrease in albuminuria is max in labetalol group. Incidence of LSCS is maximum in nifedipine group. No statistically significant difference in three groups regarding foetal outcome.

Conclusions: All three drugs are safe & effective drug in treatment of PIH. Labetalol is more effective in reducing albuminuria as compared to nifedipine & methyldopa.


Pregnancy hypertension. Cunningham Williams obstetrics. 23rd edition. New York Mc Graw Hill publishing division. 2010:706.

Brown MA, Buddle ML, Farrrell T. Randomized trial of management of hypertensive pregnancies by Korotkoff phase 4 or phase 5? Lancet. 1998;352: 777-81.

Douglas KA, Redman CWG. Eclampsia in the united Kingdom. Br med J, 1994;309:1395-400.

World Health Organization; International collaborative study of hypertensive disorders of pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J obstet gynecol. 1988;158(1):80-3.

Crowther CA. Eclampsia at Harare Maternity hospital. An epidemiological study. S Afr med. 1985;68(13):927-9.

Bergstrom S, Povey G, Songane F, Ching C. Seasonal incidence of eclampsia and its relationship to meterological data in Mozambique. J perinat Med. 1992;20(2):153-8.

Lopez-Jaramillo P, Casas JP, Serrano N. Preeclampsia: from epidemiological observations to molecular mechanisms. Braz J med Biol Res. 2001;34(10):1227-35.

Rey E, Lelorier J, Burgers E, Lange IR, Leduc L. Report of the Canadian Society consensus conference:3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1197;157(9):1245-54.

American Society of Nephrology; News release, nov.8, 2008. Available from

Sachdeva PD, Patel BG, Bhatt MV. A study of incidence and management of pregnancy induced hypertension in Central Gujrart, India. International Journal of Universal Pharmacy and Life Sciences. 2011;1(3):61-70.

Yadav S, Yadav R, Saxena U. Hypertensive disorders of pregnancy and perinatal outcome. J Obset gynecol India. 1997;17:322-30.

Sibai BM, Cunningham FG. Prevention of preeclampsia. In Lindheimer MD, Roberts JM, Cunningham FG editors: Chesley’s hypertensive Disorders of Pregnancy. 3rd edition, Elsevier, New York. 2009;215.






Original Research Articles